Merck, Inc.
🇺🇸United States
A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2013-10-09
- Last Posted Date
- 2017-09-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 461
- Registration Number
- NCT01958671
Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)
Phase 3
Terminated
- Conditions
- Amnestic Mild Cognitive ImpairmentProdromal Alzheimer's DiseaseAlzheimer's Disease
- Interventions
- Other: Placebo (Part 1)
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2019-05-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1454
- Registration Number
- NCT01953601
A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013)
Phase 1
Completed
- Conditions
- Multiple MyelomaDiffuse Large B-Cell LymphomaMyelodysplastic SyndromeHodgkin LymphomaNon-Hodgkin LymphomaFollicular LymphomaPrimary Mediastinal B-Cell Lymphoma
- Interventions
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2021-08-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 197
- Registration Number
- NCT01953692
Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)
- First Posted Date
- 2013-09-24
- Last Posted Date
- 2019-02-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 36
- Registration Number
- NCT01948986
Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants (MK-0991-064)
Phase 2
Terminated
- Conditions
- Candidiasis, Invasive
- Interventions
- First Posted Date
- 2013-09-18
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 51
- Registration Number
- NCT01945281
Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)
Phase 3
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2013-09-18
- Last Posted Date
- 2018-07-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 257
- Registration Number
- NCT01945294
The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)
Phase 1
Completed
- Conditions
- Renal ImpairmentChronic Hepatitis C
- Interventions
- First Posted Date
- 2013-09-10
- Last Posted Date
- 2019-06-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT01937975
Acute Dosing of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-003)
- First Posted Date
- 2013-09-04
- Last Posted Date
- 2018-10-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 7
- Registration Number
- NCT01934647
Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
- First Posted Date
- 2013-08-30
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 98
- Registration Number
- NCT01932762
Safety, Pharmacokinetics, and Pharmacodynamics of MK-8876 in Participants With Hepatitis C Infection (MK-8876-003)
- First Posted Date
- 2013-08-28
- Last Posted Date
- 2018-10-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 9
- Registration Number
- NCT01930058